SurgiMab: Using Antibodies to Improve Oncology Surgery

article image

SurgiMab’s fluorescence-labeled antibodies will enable surgeons to find otherwise undetectable malignancies, allowing them to remove cancers they might have previously missed, and spare healthy tissue. By Deborah Erickson.

“There is more here than meets the eye.” Sadly, this common phrase often proves all too true when it comes to cancer. Surgeons do their best to remove cancerous tissue, even allowing some extra margin when possible to be sure they get it all. But the reality is, they can’t take what they can’t see.

Perspective & Commentary

Voluntary Malfunction Summary Reporting One Year Out

The US FDA launched a voluntary summary reporting program last year to streamline reports for qualifying product malfunctions. It’s a positive step forward for the agency, but companies should weigh the pros and cons before deciding to participate. By Mir Ali, Paula Burge, and Alexander Garnick, Navigant.

Read Article